m-Diethylaminomethylbenzyl alcohol | 91271-56-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: m-Diethylaminomethylbenzyl alcohol
• 英文别名: 3-diethylaminomethyl-benzyl alcohol；3-Diaethylaminomethyl-benzylalkohol；[3-(Diethylaminomethyl)phenyl]methanol
• CAS: 91271-56-6
• 化学式: C₁₂H₁₉NO
• 分子量: 193.289
• InChiKey: BVJBYQTUAQARIY-UHFFFAOYSA-N

物化性质

• 沸点：
  160-165 °C(Press: 20 Torr)
• 密度：
  1.002±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  m-Diethylaminomethylbenzyl alcohol 在 氢溴酸 作用下， 以 水 为溶剂， 生成 N-[[3-(bromomethyl)phenyl]methyl]-N-ethylethanamine;hydrobromide
  参考文献：
  名称：

  芳族PCN钯夹钳配合物。通过与亲核试剂的反应来探究半抗原性

  摘要：

  用钯环化一系列非对称PCN钳位配体（1-（3-（（二叔丁基膦基）甲基）苯基）-N，N-二烷基甲胺）生成一系列新的PCN负载的Pd（II）氯配合物，（PCN）的PdCl（4 - 6），其中烷基=甲基，乙基，和ñ丙基，将其充分表征通过NMR光谱法和X射线晶体学。的Ñ，ñ -二甲基络合物4分发生反应用甲基锂，得到相应的甲基和二甲基络合物（PCN）PDME（12）和Li [（PCN）PDME 2 ]（13），无法分离，但已在溶液中进行了表征。（PCN）PdCl（4 – 6）与碘化物的取代反应，形成相应的碘配合物（PCN）PdI（7 – 9）是通过使用紫外可见停止流分光光度法进行研究的。实验是在甲醇中于293至325 K的温度范围内进行的。反应是可逆的，并显示仅通过溶剂配合物在两个可逆的连续步骤中进行。确定了正向和反向反应的激活参数，它们以及反应性趋势一起支持了缔合途径。没有检测到氮供体的置换，总的来说，这表明了钯上配体的半数限制。

  DOI：

  10.1021/om501231k
• 作为产物：
  描述：

  m-(diethylaminomethyl)benzylamine 在 溶剂黄146 、 sodium nitrite 作用下， 生成 m-Diethylaminomethylbenzyl alcohol
  参考文献：
  名称：

  Determination of Macronutrients, by Chemical Analysis, of Home-Prepared Milk Feeding Bottles and their Contribution to the Energy and Protein Requirements of Infants from High and Low Socioeconomic Classes

  摘要：

  Objectives: To determine the macronutrients composition of home-prepared milk feeding bottles, by chemical analysis, and assess their contribution to the energy and protein requirements of children under two years of age from high (HSE) and low (LSE) socioeconomic classes.Methods: 72 samples were analyzed for energy density and protein, fat and carbohydrate content: 41 from the LSE group and 31 from the HSE group. The assessment of the percentages of the energy and protein requirements met by the consumption of the milk bottles was calculated as follows: the energy and protein per 100 mL obtained through chemical analysis were multiplied by the volume consumed at each feeding, then by the number of feedings per day, the results divided by the energy and protein requirements and multiplied by 100. Energy and protein requirements were those recommended by the FAO/WHO/UNU Committee and the Food and Nutrition Board. The children's weight-for-age index was assessed.Results: Unmodified cow's milk was largely consumed by both groups. The addition of sugar and other ingredients to the milk was significantly higher in the LSE group. Moisture, protein and fat content were lower in the LSE group. whereas carbohydrate and energy content were higher. The percentages of energy and protein requirements provided by feeding bottles were higher in the LSE group. Children in the LSE group had lower z-scores for weight-for-age.Conclusions: Differences in the preparation practices led to differences in the chemical results. The feeding bottles in the LSE group were high in energy, due to the addition of sugar and cereals to the milk in the bottle. The milk feeding bottles were an important weaning food providing more than 50% and 100% of the children's energy and protein requirements, respectively. The children's weight-for-age index was within the normal Lb-aits.

  DOI：

  10.1080/07315724.2002.10719222

文献信息

• [EN] PYRROLIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRROLIDINE
  申请人：LILLY CO ELI

  公开号：WO2020247429A1

  公开（公告）日：2020-12-10

  The present invention provides compounds of the Formula (I) wherein L is selected from the group consisting of -CH2NHCH2-, -CH2NH-, -NH-, -S-, -S(O)-, -S(O)2-, -O-, -OCH2-, -OCH2CH2O-, -NHSO2NH-, (II) and (III), or a pharmaceutically acceptable salt thereof; a compound of the formula: (IV), processes for preparing the compounds and their salts, a pharmaceutical composition, and methods of treating patients in need of such treatment.

  本发明提供了式(I)化合物，其中L选自以下组：-CH2NHCH2-，-CH2NH-，-NH-，-S-，-S(O)-，-S(O)2-，-O-，-OCH2-，-OCH2CH2O-，-NHSO2NH-，(II)和(III)，或其药物可接受的盐；式(IV)的化合物，制备这些化合物及其盐的过程，药物组合物，以及治疗需要此类治疗的病人的方法。
• Cyclovinylogues of some Antimuscarinic Drugs
  作者：Piero Valenti、Paola Montanari、Giuseppina Fabbri、Luca Giovannini、Aduo Giacomelli

  DOI：10.1002/ardp.19853180308

  日期：——

  Syntheses of some cyclovinylogues of antimuscarinic drugs, in which a benzene ring is interposed between the methylene groups of the basic chain, are reported. The pharmacological properties of the products were investigated.

  报道了一些抗毒蕈碱药物的环乙烯基化合物的合成，其中苯环插入在基本链的亚甲基之间。对产物的药理性质进行了研究。